Related Experiment Videos
[Hepatocellular carcinoma: systemic chemotherapy, perspectives of gene or immunotherapy]
1Department Innere Medizin des Kantonsspitals Basel.
Abstract:
The systemic chemotherapy of hepatocellular carcinoma with single agent or combination chemotherapy has not resulted in reproducible response rates above 20%. Correspondingly, an effect on the survival of the treated patient population has not been shown so far. The most effective single agent is doxorubicin, which should, however, not be used outside of clinical studies in the systemic treatment of hepatocellular carcinoma. The results of hormonal treatment of hepatocellular carcinoma are also disappointing: the response rates of agents like tamoxifen, ketoconazol, nilutamid, LHRH-agonists or megestrol are usually below 10% and the survival of patients can not be improved. New approaches that are currently tested in vitro and in mouse models are pharmacological or immunological interactions with tumor cells that make use of molecular biology techniques and are summarised under the term "gene therapy". Some of these projects are in clinical phase I studies and first results can be expected in the next three to five years.
Insights
Systemic chemotherapy and hormonal treatments for hepatocellular carcinoma show limited efficacy, with response rates below 20%. Novel gene therapy approaches are under investigation and may offer future treatment options.
Area of Science:
- Hepatocellular carcinoma (HCC) research
- Medical oncology
- Molecular biology
Context:
- Systemic chemotherapy for hepatocellular carcinoma (HCC) has yielded suboptimal response rates, typically not exceeding 20%.
- Established chemotherapeutic agents like doxorubicin, while effective, are recommended only within clinical trials for HCC.
- Hormonal therapies, including tamoxifen and LHRH-agonists, have also demonstrated limited efficacy in HCC treatment, with response rates below 10%.
Purpose:
- To review the current efficacy of systemic chemotherapy and hormonal treatments for hepatocellular carcinoma (HCC).
- To highlight the limitations of existing therapeutic strategies in improving patient survival.
- To introduce emerging gene therapy approaches as potential novel treatments for HCC.
Summary:
- Current single-agent or combination chemotherapy regimens for HCC demonstrate limited and unreproducible response rates.
- Hormonal treatments for HCC have shown disappointing results, failing to improve patient survival.
- Innovative gene therapy strategies, utilizing molecular biology techniques, are being explored in preclinical and early clinical studies for HCC.
Impact:
- The findings underscore the urgent need for more effective therapeutic strategies for hepatocellular carcinoma.
- Gene therapy represents a promising frontier for HCC treatment, with early-phase clinical trials expected to yield results in the coming years.
- This review informs oncologists and researchers about the current landscape and future directions in HCC management.